Meta-analysis of clinical outcomes of intravenous recombinant tissue plasminogen activator for acute ischemic stroke: within 3 hours versus 3–4.5 hours

References

• Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics – 2010 update: a report from the American Heart Association. Circulation 2010;121:948-54
   PubMed Web of Science ®Google Scholar
• European Stroke Organisation Executive C, Committee ESOW. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507
   PubMed Web of Science ®Google Scholar
• van den Berg JS, de Jong G. Why ischemic stroke patients do not receive thrombolytic treatment: results from a general hospital. Acta Neurol Scand 2009;120:157-60
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Suri MF, Nasar A, et al. Thrombolysis for ischemic stroke in the United States: data from National Hospital Discharge Survey 1999–2001. Neurosurgery 2005;57:647-54; discussion 47-54
   PubMed Web of Science ®Google Scholar
• Katzan IL, Hammer MD, Hixson ED, et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol 2004;61:346-50
   PubMed Web of Science ®Google Scholar
• Albers GW, Olivot JM. Intravenous alteplase for ischaemic stroke. Lancet 2007;369:249-50
   PubMed Web of Science ®Google Scholar
• Hills NK, Johnston SC. Why are eligible thrombolysis candidates left untreated? Am J Prev Med 2006;31(6 Suppl 2):S210-16
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European–Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-51
   PubMed Web of Science ®Google Scholar
• Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:2019-26
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29
   PubMed Web of Science ®Google Scholar
• Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74
   PubMed Web of Science ®Google Scholar
• Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 2009;40:2438-41
   PubMed Web of Science ®Google Scholar
• Ahmed N, Wahlgren N, Grond M, et al. Implementation and outcome of thrombolysis with alteplase 3–4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-74
   PubMed Web of Science ®Google Scholar
• Alias M, Staff I, McCullough LD. Early experience with community implementation of thrombolysis three to 4.5 hours after acute ischemic stroke. Connecticut Med 2011;75:531-6
   PubMedGoogle Scholar
• Sarikaya H, Fischer A, Valko PO, et al. CT-based intravenous thrombolysis 3–4.5 hours after acute ischemic stroke in clinical practice. Neurol Res 2011;33:701-7
   PubMed Web of Science ®Google Scholar
• Shobha N, Buchan AM, Hill MD; Canadian Alteplase for Stroke Effectiveness S. Thrombolysis at 3–4.5 hours after acute ischemic stroke onset – evidence from the Canadian Alteplase for Stroke Effectiveness Study (CASES) registry. Cerebrovasc Dis 2011;31:223-8
   PubMed Web of Science ®Google Scholar
• Tekle WG, Chaudhry SA, Fatima Z, et al. Intravenous thrombolysis in expanded time window (3–4.5 hours) in general practice with concurrent availability of endovascular treatment. J Vasc Intervent Neurol 2012;5:22-6
   PubMedGoogle Scholar
• Uyttenboogaart M, Stewart RE, Vroomen PC, et al. Utility of the stroke-thrombolytic predictive instrument. J Neurol Neurosurg Psychiatry 2008;79:1079-81
   PubMed Web of Science ®Google Scholar
• Uyttenboogaart M, Vroomen PC, Stewart RE, et al. Safety of routine IV thrombolysis between 3 and 4.5 h after ischemic stroke. J Neurol Sci 2007;254:28-32
   PubMed Web of Science ®Google Scholar
• Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase 3–4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008;372:1303-9
   PubMed Web of Science ®Google Scholar
• Larrue V, von Kummer RR, Muller A, et al. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European–Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-41
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58
   PubMed Web of Science ®Google Scholar
• Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-29
   Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34
   PubMed Web of Science ®Google Scholar
• The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7
   PubMed Web of Science ®Google Scholar
• Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003;34:2847-50
   PubMed Web of Science ®Google Scholar
• Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-703
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Kirmani JF, Sayed MA, et al. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology 2005;64:2115-20
   PubMed Web of Science ®Google Scholar